Margarida Maia, PhD,  science writer—

One month of treatment with Trikafta, a triple combo of elexacaftor, tezacaftor, and ivacaftor, helped to clear mucus from the airways of adolescents and adults with cystic fibrosis (CF), a study found. Mucus became less thick, which may have helped in preventing its buildup in the airways, increasing…

Trikafta, a combination of elexacaftor, tezacaftor, and ivacaftor, lowered the number of Pseudomonas aeruginosa bacteria in the nose and sinuses of people with cystic fibrosis (CF) taking part in a small study. Mucus from the sinuses — air-filled pockets in the skull — can enter the lungs, so…

Parents of adolescents and young adults with cystic fibrosis (CF) retain a sense of responsibility for their children as they transition into adult healthcare services, and they can be frustrated by the changes demanded, an interview study reported. Healthcare providers should recognize the evolving roles of both patients and…

The Cystic Fibrosis (CF) Foundation is giving up to $9 million in additional support to advance clinical testing of ARCT-032, a messenger RNA therapy with the potential to benefit anyone with CF, regardless of their disease-causing mutation. Arcturus Therapeutics, the inhalation therapy’s developer, is using the funding…

People with cystic fibrosis (CF) in the U.S. tend to live more than a decade longer now than patients did about 20 years ago, according to a study that found deaths from CF have about halved from 1999 to 2020. “These changes were relatively slow during an earlier period…

BX004, a virus-based cocktail designed to treat Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), can reduce the number of bacteria in the lungs with no signs of resistance to treatment over time, a study has found. Findings from the first part of a small Phase 1b/2a…

Taking Orkambi (lumacaftor/ivacaftor) for more than two years helped clear trapped air from the lungs of children with cystic fibrosis (CF), ages 6-11, but didn’t prevent an abnormal widening of the airways, a real-world study finds. The findings indicate the medication may not completely stop lung damage from…

Treatment with Kaftrio, a triple combo of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., may help reduce the number of medications people with cystic fibrosis (CF) take each day, a study found. Patients may have to take multiple medications to manage all symptoms of…

Both genetics and environmental factors, such as attending daycare, family income, and maternal education, may determine how early some lung problems develop in children with cystic fibrosis (CF), a study finds. This is important because while variations in a person’s genes can’t be modified, “some extrinsic exposures can and…

The Cystic Fibrosis (CF) Foundation will put up to $2 million into an effort by Nosis Bio to use artificial intelligence (AI) to design carriers that can safely deliver gene therapy into the lungs of people with CF. “This type of therapy has the potential to treat anyone with…